Innovation & Research

Creating Tomorrow’s Therapies Today

Minnesota Urology physicians conduct a variety of clinical studies to bring the safest and most effective new urologic products and therapies to men and women suffering from urologic conditions.   

Research That Makes a Difference

At Minnesota Urology, we conduct a variety of clinical studies, from observational studies to large, randomized, controlled interventional clinical trials. We conduct Phase II and Phase III clinical trials that are especially important for getting new treatment options approved for clinical care. Our goal is to make a difference in the lives of our patients, both today and tomorrow.

STUDIES CURRENTLY OPEN FOR
ENROLLMENT OF ELIGIBLE PATIENTS

For more information or to determine if you may be eligible, call Clinical Research at 651-999-6903.

Urinary Urgency Incontinence: Males and Females

A Real World Study of eCoin® for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)

  • A multi-center, prospective, single-arm study to assess the 5-year safety and effectiveness of the eCoin® device, an FDA-approved product that provides tibial neuromodulation therapy for the treatment of overactive bladder and urinary urge incontinence, in the post-approval setting.

Treatment of Urinary Stones: Males and Females

ELS Trial: Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial

  • The purpose of this trial is to demonstrate the safety and efficacy of the Enhanced Lithotripsy System (ELS) in patients with a urinary stone within the ureter (proximal, middle, or distal).

Inflammatory Bowel Disease – Sacral Neuromodulation: Males and Females

BOOM-IBD2: Prospective, single-arm, multi-center, international clinical trial of sacral neuromodulation (SNM) in subjects with Inflammatory Bowel Disease (IBD).

  • The BOOM-IBD2 Pivotal Trial is designed to evaluate the effectiveness of SNM for the treatment of Inflammatory Bowel Disease.

Bladder Cancer: Males and Females

CORE-008: A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

QUILT-2.005: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With Alt-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer

Prostate Cancer: Males

IsoPSA Biobank: An Observational Blood Collection Study for Prostate Cancer Investigation

  • Creation of a comprehensive biorepository to facilitate internal research, analyses, and manufacturing regarding the IsoPSA assay and prostate cancer.

Benign Prostatic Hyperplasia (BPH): Males

MT-08: A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift® System in Subjects with Symptomatic Benign Prostatic Hyperplasia (BPH)

  • Post-Market Study to Assess iTind Safety Compared to UroLift

Stress Urinary Incontinence: Males

SOPHIA2: Study to assess the Safety and Effectiveness of the UrOActive® artificial urinary sPHinter In the treAtment of Stress Urinary Incontinence in Men

  • The UroActive® device is indicated to treat adult males with urinary incontinence with reduced outlet resistance due to intrinsic sphincter deficiency (ISD)

Institutional Biosafety Committee

We are a proud member of the IBC through the National Institute of Environmental Health Sciences.

Below you will find committee meeting minutes.

IBC Meeting Minutes

Help Us Foster Innovation

Minnesota Urology welcomes participants in its clinical studies. Advancements in clinical care are made possible through patient volunteers who participate in clinical research. By participating in one of our studies, patients may have access to new and innovative treatments not otherwise available. Depending on the study, they also may be eligible to receive testing, treatment, and other clinical services at no cost, as well as study patient stipends and travel compensation. For more information or to determine if you may be eligible, call Clinical Research at 651-999-6903.

Skip to toolbar